Cain Alisha M, Karpa Kelly Dowhower
York Hospital, Pennsylvania, USA.
Altern Ther Health Med. 2011 Jan-Feb;17(1):72-9.
Many patients with inflammatory bowel disease (IBD) use probiotics to manage this intestinal condition. Despite widespread use of these natural therapies by patients, health care providers may be unfamiliar with probiotics as a treatment modality. This review describes the rationale for use of probiotics in IBD, the history behind current research directions, and recent controlled clinical studies in which efficacy of probiotics has been explored in patients with IBD. Emphasis is placed upon critical analysis of study designs for investigations that used lactic acid-producing bacteria or Saccharomyces boulardii in management of Crohn's disease or ulcerative colitis. While there is suggestion of benefit when patients with ulcerative colitis use bacterial therapies and when patients with Crohn's disease use S boulardii, small sample sizes and methodological flaws in study designs necessitate that additional investigations be conducted before probiotics can be routinely recommended in clinical practice.
许多炎症性肠病(IBD)患者使用益生菌来控制这种肠道疾病。尽管患者广泛使用这些天然疗法,但医疗保健提供者可能并不熟悉益生菌作为一种治疗方式。本综述描述了在IBD中使用益生菌的基本原理、当前研究方向背后的历史,以及最近在IBD患者中探索益生菌疗效的对照临床研究。重点是对使用产乳酸菌或布拉酵母菌治疗克罗恩病或溃疡性结肠炎的研究设计进行批判性分析。虽然有迹象表明溃疡性结肠炎患者使用细菌疗法以及克罗恩病患者使用布拉酵母菌有益,但研究设计中的小样本量和方法学缺陷使得在临床实践中常规推荐益生菌之前还需要进行更多的研究。